What the evidence supports: retatrutide reduced knee osteoarthritis pain in people with obesity in clinical research. These findings do not establish cartilage regeneration. Retatrutide remains investigational in the UK. [1] [2]

For many years, we have treated knee osteoarthritis primarily as a problem inside the joint: cartilage wears, the knee becomes painful, and eventually some patients progress towards joint replacement.

I think that view is becoming too narrow.

New clinical trial evidence with retatrutide has shown substantial reductions in knee osteoarthritis pain alongside significant weight loss. To me, the important story is not simply that a new weight-loss drug may help painful knees. It is that we are beginning to see osteoarthritis through a wider lens, one that includes metabolism, body composition, inflammation, muscle function and mechanical loading, as well as the cartilage itself.

This could represent the beginning of a much more interesting field: metabolic treatment for knee osteoarthritis.

I have spent much of my career asking how we can preserve a joint rather than simply waiting until it needs replacing. Metabolic health may become another important part of that strategy.

What did the retatrutide knee osteoarthritis trial actually show?

The answer is important: retatrutide reduced knee pain.

In the knee osteoarthritis subgroup of the TRIUMPH-1 trial, which studied people with obesity, participants receiving retatrutide experienced significantly greater improvements in WOMAC knee pain than those receiving placebo over 80 weeks. WOMAC is a questionnaire used to assess osteoarthritis symptoms, including pain. [1]

These results concern the population studied. They do not establish the same benefit for a person of healthy weight with an isolated cartilage injury or meniscus tear, and a group average is not a promise of an individual outcome.

That does not mean retatrutide regenerates cartilage. It does not mean everybody with knee arthritis should receive the drug. And retatrutide is still investigational rather than an MHRA-authorised treatment in the UK. [2]

But the clinical signal matters.

Rather than asking only, “What can we inject into the knee?”, we should perhaps also be asking:

What can we change in the person to create a better environment for the knee?

Osteoarthritis is more than wear and tear

I have never particularly liked describing osteoarthritis simply as “wear and tear”.

A knee is part of a living biological system.

Its symptoms are influenced by cartilage and bone, but also by the synovium (the joint lining), muscle, mechanical loading, inflammation, body composition and wider metabolic health.

Obesity illustrates this particularly well. Additional body mass increases mechanical loading through the knee, but the relationship between obesity and osteoarthritis is not purely mechanical. Adipose tissue is metabolically active, and metabolic and inflammatory pathways are increasingly relevant to how we understand osteoarthritis.

This is why I think metabolic orthopaedics could become an important part of joint preservation.

The objective is not simply:

Lose weight, so less load goes through the knee.

A more sophisticated objective is:

Improve metabolic health + reduce excess fat + preserve or improve muscle + optimise movement + treat the joint itself where necessary.

That is a very different philosophy.

Why retatrutide is particularly interesting

Retatrutide is a triple receptor agonist acting on GLP-1, GIP and glucagon receptors. That means one medicine activates three hormone receptor pathways involved in metabolism. [3]

GLP-1, GIP and glucagon explained

GLP-1 helps regulate appetite and supports insulin release when glucose levels are raised. GIP also supports glucose-dependent insulin release. Retatrutide combines these actions with glucagon receptor activity. [3]

It is important to be precise about what this means. Glucagon and insulin have different roles in blood glucose regulation.

Insulin helps the body use and store glucose. It lowers blood glucose by encouraging glucose to move from the bloodstream into tissues, including muscle, and by reducing glucose production by the liver.

Glucagon helps maintain blood glucose between meals. It signals the liver to release glucose and also influences fat and amino-acid metabolism.

Retatrutide is therefore not acting like insulin. It is activating receptors for GLP-1, GIP and glucagon together, creating a combined metabolic effect.

Why the glucagon component matters

The glucagon component is particularly interesting because of its potential contribution to energy expenditure, the energy the body uses, and the handling of energy substrates. Early retatrutide experiments demonstrated a glucagon-related increase in energy expenditure in mice. That helps explain the rationale, but does not establish how much this mechanism contributes to sustained weight loss in people. [3]

However, I would be careful not to describe glucagon as directly “activating muscle”. We do not currently have human evidence showing that retatrutide switches on or strengthens skeletal muscle directly.

What happens to muscle during weight loss?

But muscle absolutely belongs in this conversation.

When somebody loses a substantial amount of body weight, I do not want them simply to become a smaller version of the same patient. I want to know what is happening to their muscle, strength and movement.

That matters enormously in knee osteoarthritis.

Your quadriceps help absorb load, control the knee and allow you to stand, walk and climb stairs. Losing excess fat may benefit the joint, but losing functional muscle at the same time is not the outcome I am looking for.

A human retatrutide body-composition substudy in people with type 2 diabetes found loss of lean tissue alongside fat loss, in a proportion the authors describe as similar to other obesity treatments. Lean tissue is not identical to skeletal muscle, and a body-composition scan does not establish a change in strength. The findings should not be presented as proof of automatic muscle preservation. [4]

This is why I believe metabolic treatment of osteoarthritis should ultimately be combined with objective assessment of muscle and movement. Good nutrition and appropriate exercise remain important during medically supervised weight loss. [2]

Is retatrutide regenerative medicine?

The reported knee pain results do not establish regeneration.

A treatment can reduce pain without regenerating cartilage. The knee osteoarthritis findings discussed here do not show that retatrutide regrows cartilage, reverses arthritis or prevents knee replacement. [1]

As someone working in regenerative medicine, I think we need to be particularly disciplined about that language. Pain relief is clinically valuable in its own right.

Whether metabolic optimisation could improve outcomes from cartilage repair is a separate future research question. It has not been answered by these knee pain results.

From weight loss to metabolic joint preservation

This is where I think the next generation of knee treatment becomes particularly exciting.

Imagine treating a patient with knee osteoarthritis and measuring more than their pain score and body weight.

We could potentially follow:

• body composition and metabolic health;
• muscle strength and functional capacity;
• walking, squatting and sit-to-stand performance;
• knee symptoms;
• imaging and joint structure where appropriate; and
• whether the patient is becoming more capable, rather than simply lighter.

That is much closer to my philosophy of joint preservation.

The question becomes not:

“How much weight did you lose?”

but:

Have we created a healthier biological and mechanical environment for your knee?

I use metabolic joint preservation here to describe a clinical aim: considering metabolic health alongside symptoms, strength and the joint itself. It is not a claim that retatrutide preserves cartilage structure.

Could metabolic treatment become part of knee osteoarthritis care?

I think it could.

That is my interpretation of where this field may be heading, rather than something that has already been proven.

Retatrutide is not currently an approved knee osteoarthritis treatment, and the present trials do not prove cartilage regeneration or disease modification.

But they challenge us to think differently.

For selected patients with knee osteoarthritis and metabolic disease or excess body weight, future treatment may increasingly involve treating the joint and the metabolic environment around the joint together.

That could include nutrition, medically supervised weight management where appropriate, preservation of muscle, progressive strengthening, movement optimisation and specific treatments for the knee itself.

For me, that is much more interesting than thinking of retatrutide simply as another weight-loss injection.

It is the beginning of a bigger question:

Can we improve the biology of the person to improve the future of the joint?

References and further reading

The TRIUMPH-1 source linked here is a manufacturer conference presentation. The mechanistic and body-composition papers answer different research questions.

1. Lilly: TRIUMPH-1 Phase 3 results, ADA Scientific Sessions, June 2026 (conference presentation).
2. MHRA: No summer shortcut for safe weight loss, 24 July 2026.
3. Coskun et al. LY3437943: from discovery to clinical proof of concept. Cell Metabolism, 2022.
4. Coskun et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 randomised trial. Lancet Diabetes & Endocrinology, 2025.